PROLIFIC (Prognostic Lung Fibrosis Consortium)
PROLIFIC (Prognostic Lung Fibrosis Consortium) supports research organizations and industry partners in developing blood biomarker assays to advance pulmonary fibrosis drug development and tailored treatment.
Funder: Pulmonary Fibrosis Foundation
Due Dates: Open to new membership inquiries
Funding Amounts: Research funded by PROLIFIC consortium members
Summary: PROLIFIC brings research organizations and industry partners together to develop and validate blood protein biomarker assays for pulmonary fibrosis drug development and targeted treatment.
Description
PROLIFIC, the Prognostic Lung Fibrosis Consortium, was launched by the Pulmonary Fibrosis Foundation (PFF) and Bristol Myers Squibb to advance scientific exploration and drug development for pulmonary fibrosis. Pharmaceutical companies and foundations collaborate across competitors to develop a company-agnostic assay for use during drug development. The consortium aims to identify early indicators of drug activity and, ultimately, biomarkers that predict which patients would benefit most from particular treatments.
Members focus on 12 blood protein biomarkers spanning epithelial damage, fibrosis, inflammation, and thrombosis. Research uses patient samples from the PFF Registry and its biorepository to identify and validate biomarkers and multi-assay panels. The work includes developing assays suitable as exploratory, prognostic, or predictive biomarkers in idiopathic pulmonary fibrosis (IPF) clinical trials, with the longer-term goal of helping physicians tailor therapies.
